Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
We evaluated the safety and efficacy of an optimized adeno-associated virus (AAV; AAV2.RPE65) in animal models of the RPE65 form of Leber congenital amaurosis (LCA). Protein expression was optimized by addition of a modified Kozak sequence at the translational start site of hRPE65. Modifications in AAV production and delivery included use of a long stuffer sequence to prevent reverse packaging from the AAV inverted-terminal repeats, and co-injection with a surfactant. The latter allows consistent and predictable delivery of a given dose of vector. We observed improved electroretinograms (ERGs) and visual acuity in Rpe65 mutant mice. This has not been reported previously using AAV2 vectors. Subretinal delivery of 8.25 x 10(10) vector genomes in affected dogs was well tolerated both locally and systemically, and treated animals showed improved visual behavior and pupillary responses, and reduced nystagmus within 2 weeks of injection. ERG responses confirmed the reversal of visual deficit. Immunohistochemistry confirmed transduction of retinal pigment epithelium cells and there was minimal toxicity to the retina as judged by histopathologic analysis. The data demonstrate that AAV2.RPE65 delivers the RPE65 transgene efficiently and quickly to the appropriate target cells in vivo in animal models. This vector holds great promise for treatment of LCA due to RPE65 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jean Bennett's group enhanced safety and maximized the therapeutic effect by adding a stuffer sequence for rAAV product hRPE65v2 [39,226].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [226]
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationDOUGLAS, R. M., ALAM, N. M., SILVER, B. D., MCGILL, T. J., TSCHETTER, W. W., & PRUSKY, G. T. (2005) · Visual Neuroscience · doi:10.1017/s0952523805225166 · Cited by 405
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Lyubarsky, A. L., Falsini, B., Pennesi, M. E., Valentini, P., & Pugh, E. N. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00442.1999 · Cited by 273
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Aguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationPang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings
Lyubarsky, A., & Pugh, E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00563.1996 · Cited by 225
Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction.
Bennett, J., Duan, D., Engelhardt, J. F., & Maguire, A. M. (1997) · PubMed · Cited by 204
Self-citation
Cited by
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Self-citationHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
“This self-reported increase in visual sensitivity posttreatment is earlier than times previously reported in most animal studies (2, 8, 9, 12, 14).”
ResultSimonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Self-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Self-citationDias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
“The transgene cassette in the AAV2-hRPE65v2 vector carries a chicken b-actin promoter driving expression of the human RPE65 complementary DNA with an optimized Kozak sequence (14).”
BackgroundSelf-citationLeader of the pack: gene mapping in dogs and other model organisms
Karlsson, E. K., & Lindblad-Toh, K. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2382 · Cited by 298
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
“promoter design and transgene codon optimization), the manufacturing process and resulting final product purity and the product formulation (29).”
BackgroundSelf-citationLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
Weleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“(105) under the terms of the CC BY-NC-ND 4.”
Backgroundden Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42258 · Cited by 207
Self-citationManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Self-citationClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Self-citationAdeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“injected behind the retina of animal models of LCA2 resulted in rapid development of visual function (Bennicelli et al., 2008).”
BackgroundInfluentialModeling and Rescue of RP2 Retinitis Pigmentosa Using iPSC-Derived Retinal Organoids
Lane, A., Jovanovic, K., Shortall, C., Ottaviani, D., Panes, A. B., Schwarz, N., Guarascio, R., Hayes, M. J., Palfi, A., Chadderton, N., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.05.007 · Cited by 181
“AAV-containing fractions were dialyzed against PBS supplemented with Pluronic F68 (0.001%; Bennicelli et al., 2008).”
MethodInfluentialLock, M., Alvira, M. R., Chen, S.-J., & Wilson, J. M. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.131 · Cited by 163
“It has been noted that considerable loss of vector can occur during the titering process through binding to plastic surfaces at low vector dilutions and that this can be overcome by inclusion of a surfactant in the vector preparation itself or in dilution buffers (Bennicelli et al., 2008).”
BackgroundRPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Ophthalmic Genetics · doi:10.1080/13816810802626399 · Cited by 162
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
“RPE65 (Bennicelli et al. 2008).”
BackgroundSelf-citationEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Self-citationHellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
“Assays on PBMCs were performed as previously described (20, 36).”
InfluentialSelf-citationThe human visual cortex responds to gene therapy–mediated recovery of retinal function
Ashtari, M., Cyckowski, L. L., Monroe, J. F., Marshall, K. A., Chung, D. C., Auricchio, A., Simonelli, F., Leroy, B. P., Maguire, A. M., Shindler, K. S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57377 · Cited by 138
Self-citationClinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
“Human and canine RPE65 expressionwhen delivered by AAV vectors has since been shown to be consistent and long-lived, with ERG response stable for over three years (Acland et al., 2005; Bennicelli et al., 2008).”
BackgroundChung, D. C., & Traboulsi, E. I. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.10.004 · Cited by 138
Self-citationFoster, H., Sharp, P. S., Athanasopoulos, T., Trollet, C., Graham, I. R., Foster, K., Wells, D. J., & Dickson, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.186 · Cited by 119
“This observation is in accordance with recent data which demonstrate optimised protein expression of eukaryotic genes through either incorporation of a Kozak sequence (18) or codon optimisation (19).”
Patel, P., Kriz, J., Gravel, M., Soucy, G., Bareil, C., Gravel, C., & Julien, J.-P. (2014) · Molecular Therapy · doi:10.1038/mt.2013.239 · Cited by 110
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Self-citationCell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases
Jones, M. K., Lü, B., Girman, S., & Wang, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.004 · Cited by 125
“Using animal models of LCA, subretinal injections of adeno-associated virus (AAV) mediated RPE65 gene delivery was able to restore vision (Acland et al., 2005, 2001; Bennicelli et al., 2008).”
MethodGene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
“Among these genes, the RPE65 gene, expressed in RPE cells, encodes a 65 kDa specific protein that catalyzes the conversion of all-trans retinyl esters to 11-cis retinal [156].”
ResultInfluentialdel Pozo‐Rodríguez, A., Pujals, S., Delgado, D., Solinís, M. Á., Rodríguez‐Gascón, A., Giralt, E., & Pedraz, J. L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.004 · Cited by 106
Jo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, D., Kim, J. H., Kim, J.-S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 102
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Jang, J.-H., Koerber, J. T., Kim, J.-S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K. I., & Schaffer, D. V. (2011) · Molecular Therapy · doi:10.1038/mt.2010.287 · Cited by 101
del Pozo‐Rodríguez, A., Delgado, D., Solinís, M. Á., Rodríguez‐Gascón, A., & Pedraz, J. L. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.023 · Cited by 100
Cecchini, S., Virag, T., & Kotin, R. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.250 · Cited by 97
“, subretinal injection for treating Leber’s congenital amaurosis (Bennicelli et al., 2008; Maguire et al., 2008, 2009), therapeutic doses of rAAV are readily obtained from a relatively small number of rAAV producer cells.”
BackgroundTolmachova, T., Tolmachov, O. E., Barnard, A. R., de Silva, S. R., Lipinski, D. M., Walker, N. J., MacLaren, R. E., & Seabra, M. C. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1006-4 · Cited by 91
“Although one might argue that other serotypes such as AAV8 may be more efficient in targeting photoreceptors, AAV2 with the CBA promoter remains the gold standard for retinal transduction as evidenced by the sustained vision in Briard dogs treated with AAV2 vector over a decade ago [35].”
BackgroundBoth Ends of the Leash — The Human Links to Good Dogs with Bad Genes
Ostrander, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204453 · Cited by 99
High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography
Florea, M., Nicolaou, F., Pacouret, S., Zinn, E. M., Sanmiguel, J. C., Andrés‐Mateos, E., Unzu, C., Wagers, A. J., & Vandenberghe, L. H. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.009 · Cited by 98
“Pluronic F-68 is a non-ionic surfactant that has been shown to decrease AAV non-specific binding to various surfaces including plasticware.(24,25) As HPLC contains long and narrow plastic tubing, we reasoned that addition of Pluronic F-68 may increase purification efficiency by reducing AAV binding to plastic.”
BackgroundAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Bush, R. A., Zeng, Y., Colosi, P., Kjellstrom, S., Hiriyanna, S., Vijayasarathy, C., Santos, M., Li, J., Wu, Z., & Sieving, P. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.142 · Cited by 86
Halting progressive neurodegeneration in advanced retinitis pigmentosa
Koch, S. F., Tsai, Y.-T., Duong, J. K., Wu, W.-H., Hsu, C.-W., Wu, W.-P., Bonet-Ponce, L., Lin, C.-S., & Tsang, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82462 · Cited by 86
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Gene therapy in the second eye of RPE65-deficient dogs improves retinal function
Annear, M. J., Bartoe, J. T., Barker, S. E., Smith, A. J., Curran, P. G., Bainbridge, J. W., Ali, R. R., & Petersen-Jones, S. M. (2011) · Gene Therapy · doi:10.1038/gt.2010.111 · Cited by 74
Weleber, R. G., Michaelides, M., Trzupek, K. M., Stover, N. B., & Stone, E. M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6106 · Cited by 74
A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71
“Many clinical trials testing AAV-based therapies for LCA associated with RPE65 and LRAT deficiency are underway based on extensive preliminary research using animal models [3,12,13].”
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Self-citationOcular gene therapy: current progress and future prospects
Colella, P., Cotugno, G., & Auricchio, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.003 · Cited by 78
Quantitative and Digital Droplet-Based AAV Genome Titration
Sanmiguel, J., Gao, G., & Vandenberghe, L. H. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9139-6_4 · Cited by 67
“poloxamer 188 solution, is a BASF registered trademark of a 10% solution of polyoxyethylenepolyoxypropylene block copolymer, a nonionic surfactant that serves to prevent AAV attachment to plastic [20, 26].”
BackgroundResults at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy
Pennesi, M. E., Weleber, R. G., Yang, P., Whitebirch, C., Thean, B., Flotte, T. R., Humphries, M., Chegarnov, E., Beasley, K. N., Stout, J. T., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.014 · Cited by 68
Long-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
Self-citationStem cells for investigation and treatment of inherited retinal disease
Tucker, B. A., Mullins, R. F., & Stone, E. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu124 · Cited by 74
Leber Hereditary Optic Neuropathy: Exemplar of an mtDNA Disease
Wallace, D. C., & Lott, M. T. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_2 · Cited by 67
Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations
Katz, J. S., Chou, D. K., Christian, T. R., Das, T. K., Patel, M., Singh, S. N., & Wen, Y. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.12.002 · Cited by 66
Evaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
MicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60
“Assuming that the CBA expression pattern following subretinal administration of AAV2/2 vectors in the human retina is similar to that observed in mice and dogs [47,48], we are presumably misexpressing the RPE65 in PRs in addition to the RPE.”
BackgroundMechanisms of blindness: Animal models provide insight into distinct CRX ‐associated retinopathies
Tran, N. M., & Chen, S. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24151 · Cited by 64
“These approaches have successfully been used to improve retinal function in animal models of retinal dystrophies (Acland et al., 2001; Bennicelli et al., 2008; Boye et al., 2010; Jiang et al., 2011; Mancuso et al., 2009; O’Reilly et al., 2007; Tam et al., 2008), as well as in human safety trials…”
MethodBarker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
Dog Models for Blinding Inherited Retinal Dystrophies
Petersen-Jones, S. M., & Komáromy, A. M. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.155 · Cited by 59
Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector
Barnard, A. R., Groppe, M., & MacLaren, R. E. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017293 · Cited by 60
“RPE65 show that the treated dogs maintain vision without reduction for several years, and even over a decade in some cases (Bennicelli et al. 2008; Cideciyan et al. 2013).”
BackgroundMethodInfluentialGene supplementation therapy for recessive forms of inherited retinal dystrophies
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.161 · Cited by 66
Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 57
Gene therapy in inherited retinal degenerative diseases, a review
Takahashi, V. K. L., Takiuti, J. T., Jauregui, R., & Tsang, S. H. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1495745 · Cited by 57
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa
Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M., & Tsang, S. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds466 · Cited by 55
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
McDougald, D. S., Dine, K. E., Zezulin, A. U., Bennett, J., & Shindler, K. S. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22972 · Cited by 53
Self-citationCurrent Concepts in the Treatment of Retinitis Pigmentosa
Musarella, M. A., & MacDonald, I. M. (2010) · Journal of Ophthalmology · doi:10.1155/2011/753547 · Cited by 60
“The authors also wish to thank the Foundation Fighting Blindness USA and Canada for providing funding to seek current therapies.”
BackgroundInfluentialThe Genomic Response of the Retinal Pigment Epithelium to Light Damage and Retinal Detachment
Rattner, A., Toulabi, L., Williams, J., Yu, H., & Nathans, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2401-08.2008 · Cited by 50
“The viral gene transfer strategy has been used in Rpe65 deficient rodent and dogs (Bennicelli et al., 2008), and it is currently in human clinical trials (Bainbridge et al.”
MethodNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
“Delivery of the RPE65 gene to RPE cells in the retina of dogs (41, 42) and mice (43, 44) showed long-term improvement of retinal function and few adverse effects leading to the initiation ofthe different clinical trials.”
BackgroundLyons, L. A., Creighton, E. K., Alhaddad, H., Beale, H. C., Grahn, R. A., Rah, H., Maggs, D. J., Helps, C. R., & Gandolfi, B. (2016) · BMC Genomics · doi:10.1186/s12864-016-2595-4 · Cited by 54
“Indeed, gene therapy for canine Leber’s congenital amaurosis (LCA) has restored vision to the blind [19] and a variety of LCA clinical trials are underway in human patients [20–23].”
BackgroundAdipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 54
Treharne, A. J., Grossel, M. C., Lotery, A. J., & Thomson, H. A. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.184002 · Cited by 55
Ku, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F. X., Li, T., Hauswirth, W. W., & Ramamurthy, V. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr391 · Cited by 46
SubILM Injection of AAV for Gene Delivery to the Retina
Gamlin, P. D., Alexander, J. J., Boye, S. L., Witherspoon, C. D., & Boye, S. E. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9139-6_14 · Cited by 46
The use of canine models of inherited retinal degeneration to test novel therapeutic approaches
Beltran, W. A. (2009) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2009.00694.x · Cited by 55
Li, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed · Cited by 52
Thurtell, M. J., & Leigh, R. J. (2010) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3181e7518f · Cited by 45
“Gene therapy offers great promise for those individuals with hereditary retinal disorders that are associated with nystagmus (83).”
BackgroundSodi, A., Banfi, S., Testa, F., Della Corte, M., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
Gene therapy for Leber congenital amaurosis: advances and future directions
Hufnagel, R. B., Ahmed, Z. M., Corrêa, Z. M., & Sisk, R. A. (2012) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2028-2 · Cited by 44
Ashtari, M., Nikonova, E. S., Marshall, K. A., Young, G. J., Aravand, P., Pan, W., Ying, G.-S., Willett, A. E., Mahmoudian, M., Maguire, A. M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.01.029 · Cited by 44
Self-citationGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
Efficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42
Gene Therapy Targeting Glaucoma: Where Are We?
Liu, X., Rasmussen, C. A., Gabelt, B. T., Brandt, C. R., & Kaufman, P. L. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.04.003 · Cited by 42
“ERG responses confirmed the reversal of visual deficit.(13) These studies demonstrate that AAV vector holds great promise for treatment of retinal disorders such as LCA and provides useful information relevant to glaucoma gene therapy such as neuroprotection or rescue of glaucomatous optic nerve damage at an early sta…”
QLT091001, a 9-cis-Retinal Analog, Is Well-Tolerated by Retinas of Mice with Impaired Visual Cycles
Maeda, T., Dong, Z., Jin, H., Sawada, O., Gao, S., Utkhede, D., Monk, W., Palczewska, G., & Palczewski, K. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-11152 · Cited by 41
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Nystagmus and saccadic intrusions
Thurtell, M. J., & Leigh, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52903-9.00019-4 · Cited by 42
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
MacLachlan, T. K., Milton, M. N., Turner, O., Tukov, F., Choi, V. W., Penraat, J., Hanks, S. M., Vrouvlianis, J., Leehy, B., Li, H., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.001 · Cited by 40
Hauswirth, W. W., Alemán, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.107 · Cited by 47
The ice age – A review on formulation of Adeno-associated virus therapeutics
Grossen, P., Skaripa-Koukelli, I., van Haasteren, J., Machado, A. H. E., & Dürr, C. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.002 · Cited by 43
Animal models for metabolic, neuromuscular and ophthalmological rare diseases
Vaquer, G., Rivière, F., Mavris, M., Bignami, F., Llinares, J., Westermark, K., & Sepodes, B. M. N. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3831 · Cited by 43
AAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models
Stieger, K., Lheriteau, E., Moullier, P., & Rolling, F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.206 · Cited by 37
Maria, M., Ajmal, M., Azam, M., Waheed, N. K., Siddiqui, S. N., Mustafa, B., Ayub, H., Ali, L., Ahmad, S., Micheal, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119806 · Cited by 39
“For example, AAV-based gene therapy has been shown to be successful in a CRD dog model and in humans with RPE65-associated LCA [52–57], as well as in choroideremia subjects [58].”
Background
Metadata
- Authors
- Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., Wei, Z., Qu, G., Zhou, S., Zeiss, C., Arruda, V. R., Acland, G. M., Dell'Osso, L. F., High, K. A., Maguire, A. M., & Bennett, J.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Case Western Reserve University (US)
- Yale University (US)
- Cornell University (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 458-465
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2842085
- OpenAlex
- W2035101755
- Cited by
- 267
- References
- 25
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 16 · 2023: 13 · 2022: 14 · 2021: 15 · 2020: 17 · 2019: 13 · 2018: 10 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 18 · 2013: 11 · 2012: 16
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- F. M. Kirby Foundation
- Research to Prevent Blindness
- Macula Vision Research Foundation
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY015398, R01EY006855, K12EY015398)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Leber congenital amaurosis, RPE65, AAV2, gene therapy, adeno-associated virus vectors, subretinal injection, retinal pigment epithelium, vector safety, electroretinogram, visual acuity, nystagmus, canine model, vector production
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Dogs, Electroretinography, Eye Proteins, Genetic Vectors, Immunohistochemistry, Mice, Knockout, cis-trans-Isomerases, Optic Atrophy, Hereditary, Leber, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.